Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBibiana Bielekova, Matthew L. Herman
Estimating the term…
Described herein are methods of treating multiple sclerosis (MS), such as secondary progressive MS (SPMS), by intrathecally administering a B cell depleting agent, such as rituximab, alone or in combination with intravenous administration of a B cell depleting agent. Also described is the use of IL-12p40, CXCL13, or both as CSF biomarkers for selecting a patient with progressive MS as a candidate for treatment with an intrathecal immunomodulatory therapy, and for identifying a progressive MS patient as having meningeal inflammation. The present disclosure also describes a method of evaluating the effectiveness of a therapy for treating progressive MS by measuring the level of IL-12p40, CXCL13, or both in the CSF of the patient before and after treatment. A decrease in the level of IL-12p40, CXCL13, or both after treatment indicates the therapy is effective for treating progressive MS.
A method of treating a subject having multiple sclerosis (MS), comprising selecting a subject with MS and administering to the subject a therapeutically effective amount of rituximab into the cerebral spinal fluid (CSF), thereby treating the subject with MS.
(canceled)
11-12. (canceled)
(canceled)
21-22. (canceled)
A method of treating a subject having multiple sclerosis (MS), comprising:
(canceled)
30-31. (canceled)
A method of evaluating the effectiveness of a therapy in a subject having MS, comprising measuring the level of IL-12p40, CXCL13, or both in the CSF of the patient before and after treatment with the therapy, wherein a decrease in the level of IL-12p40, CXCL13, or both after treatment compared to before treatment indicates the therapy is effective.
A method of selecting a patient having progressive MS as a candidate for treatment with an intrathecal immunomodulatory therapy, or a method of identifying a progressive MS patient as having meningeal inflammation, comprising measuring the level of IL-12p40, CXCL13, or both in the CSF of the patient, wherein an increase in the level of IL-12p40, CXCL13, or both relative to a control, indicates the subject is a candidate for treatment with an intrathecal immunomodulatory therapy, or indicates that the MS patient has meningeal inflammation.
34-43. (canceled)
Dependencies are inferred from the claim text.